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In 007, an estimated 6,400 Iowans will die from cancer,  
5 times the number caused by auto fatalities. Cancer is  
second only to heart disease as a cause of death. These 
projections are based upon mortality data the State Health 
Registry of Iowa receives from the Iowa Department  
of Public Health. The Registry has been recording the  
occurrence of cancer in Iowa since 973, and is one of  
fourteen population-based registries and three  
supplementary registries nationwide providing data to  
the National Cancer Institute. With 2007 Cancer in Iowa  
the Registry makes a general report to the public on the  
status of cancer. This report will focus on: 
 • a description of the Registry and its goals; 
 • cancer estimates for 007; 
 • a special section on Iowa’s progress toward  
   cancer mortality goals for the year 00; 
 • brief summaries of recent/ongoing research  
   projects; 
 • a selected list of publications from 006.
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3THE STATE HEALTH REGISTRY  
OF IOWA IS THE BEST 
STATEWIDE RESOURCE FOR 
DETERMINING THE BURDEN 
OF CANCER ON THE IOWA 
POPULATION AND ASSESSING 
TRENDS IN THE OCCURRENCE  
OF CANCER OVER TIME. 
The State Health Registry of Iowa
 
ancer is a reportable disease as stated in the Iowa Administrative Code.  
Cancer data are collected by the State Health Registry of Iowa, located at 
The University of Iowa in the College of Public Health’s Department of 
Epidemiology. The staff includes more than 50 people. Half of them, situated 
throughout the state, regularly visit hospitals, clinics, and medical laboratories  
in Iowa and neighboring states to collect cancer data. A follow-up program tracks 
more than 99 percent of the cancer survivors diagnosed since 973. This program 
provides regular updates for follow-up and survival. The Registry maintains the 
confidentiality of the patients, physicians, and hospitals providing data.
In 007 data will be collected on an estimated 5,700 new cancers among 
Iowa residents. In situ cases of bladder cancer are included in the estimates for 
bladder cancer, to be in agreement with the definition of reportable cases of 
the Surveillance, Epidemiology, and End Results (SEER) Program of the National 
Cancer Institute. 
Since 973 the Iowa Registry has been funded by the SEER Program of the 
National Cancer Institute. Iowa represents rural and Midwestern populations 
and provides data included in many NCI publications. Beginning in 990 about 
5-0 percent of the Registry’s annual operating budget has been provided  
by the state of Iowa. Beginning in 003, the University of Iowa has also been  
providing cost-sharing funds. In addition, the Registry receives funding  
through grants and contracts with university, state, and national researchers 
investigating cancer-related topics.
The goals of the Registry are to:
*  assemble and report measurements of cancer incidence, survival and  
 mortality among Iowans;
*  provide information on changes over time in the extent of disease at  
 diagnosis, therapy, and patient survival;
*  promote and conduct studies designed to identify factors relating to  
 cancer etiology, prevention and control; 
*  respond to requests from individuals and organizations in the state of  
 Iowa for cancer data and analyses; 
*  provide data and expertise for cancer research activities and  
 educational opportunities. 
C

5New Cancers in Females
Type	 #	of	Cancers	 %	of	Total
Breast	 2100	 27.3
Lung	 950	 12.4
Colon	&	rectum	 940	 12.2
Uterus	 480	 6.2
Non-Hodgkin’s	lymphoma	 380	 4.9
Skin	melanoma	 280	 3.7
Ovary	 240	 3.1
Thyroid	 230	 3.0
Bladder	(invasive	and	noninvasive)	 210	 2.7
Leukemia	 210	 2.7
All	others	 1680	 21.8
Total	 7700
New Cancers in Males
Type	 																#	of	Cancers										%	of	Total
Prostate	 2100	 26.3
Lung	 1250	 15.6
Colon	&	rectum	 950	 11.9
Bladder	(invasive	and	noninvasive)	 600	 7.5
Non-Hodgkin’s	lymphoma	 400	 5.0
Skin	melanoma	 300	 3.7
Kidney	&	renal	pelvis	 290	 3.6
Leukemia	 260	 3.2
Oral	cavity	 200	 2.5
Pancreas	 190	 2.4
All	others	 1460	 18.3
Total	 8000
Top 10 Types of Cancer in Iowa Estimated for 2007
Fortunately for Iowans, the chances of being diagnosed with many types of cancer can be 
reduced through positive health practices such as smoking cessation, physical exercise, healthful 
dietary habits, and alcohol consumption in moderation. Early detection through self-examination 
and regular health checkups can improve cancer survival. 
Cancer Deaths in Females
Type	 															#	of	Cancers									%	of	Total
Lung	 780	 25.2
Breast	 410	 13.2
Colon	&	rectum	 330	 10.6
Pancreas	 190	 6.1
Ovary	 180	 5.8
Non-Hodgkin’s	lymphoma	 130	 4.2
Leukemia	 130	 4.2
Uterus	 100	 3.2
Brain	 80	 2.6
Kidney	&	renal	pelvis	 70					 2.3
All	others	 700	 22.6
Total	 3100
Cancer Deaths in Males
Type	 															#	of	Cancers				 %	of	Total
Lung	 1100	 33.3
Prostate	 350	 10.6
Colon	&	rectum	 330	 10.0
Leukemia	 170	 5.2
Pancreas	 170	 5.2
Non-Hodgkin’s	lymphoma	 140	 4.3
Esophagus	 130	 3.9
Bladder	 110	 3.3
Kidney	&	renal	pelvis	 100	 3.0
Brain	 90	 2.7
All	others	 610	 18.5
Total	 3300
6Table 1. Progress toward cancer mortality goals in  
Healthy Iowans 2010*     
Healthy Iowans 2010 is a health 
plan for the state of Iowa and is  
a companion to the national 
plan, Healthy People 2010.  
Herein progress made toward  
the Healthy Iowans 2010 cancer 
mortality goals is updated. 
Table  shows the cancer sites 
included in Healthy Iowans 
2010. All cancer sites combined 
is included, as well as specific 
cancer sites where modifiable 
risk factors have been identified 
and/or screening guidelines are 
practiced. The baseline mortal-
ity rate is given for 994-996,  
the most recent data available 
at the time Healthy Iowans 
2010 was initially developed. 
To monitor progress, the rates 
for the years 003-005 are 
now available and the percent 
improvement can be calculated 
over these two time periods. 
Improvement is seen at each 
site and the magnitude has been 
double-digit for prostate, female 
breast, colorectal, and cervical 
cancers. The goal for the year 
00 is also presented, to see 
how much work is still needed 
to meet the established goal. 
The 003-005 prostate can-
cer rate indicates the Healthy 
Iowans 2010 goal has already 
been reached for this can-
cer. Even though the percent 
improvement for lung cancer 
was small, the number of lives 
saved is large because this is  
the leading cause of cancer  
mortality. 
Indirect standardization is a  
statistical technique that allows 
for the conversion of percent 
improvements into the number 
of lives saved. For this report, 
the number of lives saved was 
estimated for the years 997-005 
using this technique. Indirect 
standardization assumes the 
age- and gender-specific rates 
from 994-996 and applies them 
to age- and gender-specific Iowa 
census populations for each 
of the years 997-005 to yield 
the expected number of cancer 
deaths. The observed number of 
deaths is obtained by summing 
the number of deaths in speci-
fied years where the cancer site 
is listed as the underlying cause 
of death on the death certifi-
cate. The number of lives saved 
can be estimated by subtracting 
the observed number of cancer 
deaths for the years 997-005 
from the expected number of 
deaths. Table  presents these 
Iowa’s Progress toward Cancer Mortality Goals  
for the Year 2010
	 	 1994-1996		 			 	 		
	 	 Baseline			 2003-2005		 2010
Cancer	Site	 			Gender+	 Rate§	 Rate§	 Rate	Goal§
	 		 		 	 	 	
All	sites	 M	&	F	 196.4	 182.8	 173.0	 6.9%
Prostate	 M	 36.0	 26.0	 26.0	 27.8%
Breast	 F	 29.0	 22.1	 19.0	 23.8%
Colon	&	rectum	 M	&	F	 23.2	 18.7	 15.5	 19.4%
Cervix	 F	 2.6	 2.2	 1.9	 15.4%
Skin	melanoma	 M	&	F	 2.5	 2.4	 1.9	 4.0%
Oral	cavity	&	pharynx	 M	&	F	 2.6	 2.5	 1.8	 3.8%
Lung	 M	&	F	 54.1	 53.1	 46.0	 1.8%
*	The	complete	cancer	chapter	is	available	at	http://www.idph.state.ia.us/bhpl/common/pdf/
healthy_iowans_2010_chapters/Healthy_Iowans_2010_Complete.pdf
+	M=male;	F=female.
§	Expressed	per	100,000	and	age-adjusted	to	the	2000	U.S.	standard	population.	
ŧ Determined	by	subtracting	the	2003-2005	rate	from	the	1994-96	baseline	rate	and	dividing		
by	the	1994-96	baseline	rate.	
Percent	
Improvementŧ
7numbers by cancer site and 
gender. For the time period 
997-005, 3,066 lives have been 
saved from cancer death, ,03 
attributed to males and 963  
to females.     
Figure  shows how these 
3,066 lives are distributed 
over the years 997-005. The 
expected number of cancer 
deaths increases each year 
because the population is both 
increasing in absolute numbers 
and proportionally increasing 
in older age groups. Meanwhile, 
the number of observed cancer 
deaths has remained steady at 
around 6,400 deaths annually. 
The net result is a greater  
number of lives saved in the 
more recent years.  
For cancer prevention and 
control purposes it is important 
to evaluate additional charac-
teristics in the population to 
see how the lives saved are 
distributed. In Table 3 data are 
presented by gender, age, race, 
and urban/rural status. The 
standardized mortality ratio 
(SMR) was calculated by divid-
ing the observed number of 
cancer deaths by the expected 
number of these deaths. The 
SMR provides a simple way to 
look at progress. When the SMR 
is less than , it means prog-
ress is being made. When the 
SMR is greater than , it means 
that more cancer deaths were 
seen than expected. In females, 
progress has been made in all 
areas except for those 75 years 
of age or older and those who 
are black. In males there is also 
a need for improvement among 
blacks and those aged 0-9 years. 
Overall, the progress has been 
widespread across the state with 
a noticeable racial disparity.
The greatest improvements 
in mortality rates to date are 
seen with prostate, colorectal, 
female breast, and male lung 
cancers. These are the same 
cancer sites that for years have 
been responsible for over 50% of 
Percent	
Improvementŧ
Table 2. Distribution of 3,066 estimated lives saved by 
cancer site and gender, Iowa, 1997-2005
	 	 	 	
	 	 Observed	 Expected	 Difference
	 	 number	of	 number	of	 “+”	=	lives	saved
Cancer	site	 Gender	 deaths	 deaths*	 “-“	=	lives	lost
	 	 	 	
All	sites	 M	 29,881	 31,984	 +	2,103
	 F	 27,649	 28,612	 +	963
Prostate	 M	 3,571	 4,411	 +	840
Breast	 F	 4,172	 4,880	 +	708
Colon	&	rectum	 M	 3,206	 3,508	 +	302
	 F	 3,358	 3,850	 +	492
Cervix	 F	 342	 389	 +	47
Skin	melanoma	 M	 448	 459	 +	11
	 F	 272	 280	 +	8
Oral	cavity	&	pharynx	 M	 453	 486	 +	33
	 F	 255	 303	 +	48
Lung	 M	 9,427	 10,409	 +	982
	 F	 6,255	 5,932	 -	323
All	other	sites	 M	 12,776	 12,711	 -65
	 F	 12,995	 12,978	 -17
*	Computed	using	indirect	standardization	with	sex-	and	age-specific	rates	for	
1994-1996	as	the	standard		
cancer deaths in Iowa. Cancer 
mortality rates are primarily 
affected by incidence rates (the 
rate at which new cancers are 
diagnosed), screening tests avail-
able (to detect cancers earlier), 
and treatment. The decline in 
male lung cancer deaths can be 
attributed to declines in ciga-
rette smoking, thereby reducing 
the number of new lung cancer 
cases being diagnosed. When 
Table  was repeated among 
males for newly diagnosed can-
cers rather than cancer deaths, 
the number of new lung can-
cers observed over the period 
997-004 was 900 fewer than 
expected. A recent published 
report indicates that mammog-
raphy screening and improved 
treatments have equally contrib-
uted to the fewer women dying 
from breast cancer. Reductions 
in breast cancer incidence have 
not been seen. A recent publica-
tion also indicated that currently 
available interventions could 
reduce colorectal cancer mortal-
ity by 50% by the year 00 with 
most of this reduction coming 
from increased screening fol-
lowed by decreasing risk factor 
prevalence. The reasons for the 
decline in the prostate cancer 
mortality rates are not as well 
understood. The prostate 
specific antigen (PSA) screen-
ing test is available for prostate 
cancer, but the clinical trials are 
not complete yet on the effec-
tiveness of this test in reducing 
prostate cancer mortality. 
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Figure 1. Estimated Lives Saved from Cancer Death, Iowa 
	 	 	 	
*	Computed	using	indirect	standardization	with	sex-	and	age-specific	rates	for	1994-1996	as	the	standard.	
9Table 3. Distribution of 3,066 estimated lives saved from 
a cancer death by gender and characteristic, Iowa, 1997-2005 
	 	 	 	
	 	 	 	 Difference	 	
	 	 Observed		 Expected	 “+”	=	lives
	 	 number	 number	 saved
Gender	 Characteristic	 of	deaths	 of	deaths§	 “-“	=	lives	lost	 SMR*
	
	 	 	 	
Female	 Age		 	 	 	
	 					0-19	 87	 107	 +20	 0.81ŧ
	 					20-44	 916	 1052	 +136	 0.87ŧ
	 					45-64	 5818	 6546	 +728	 0.89 ŧ
	 					65-74	 6495	 6734	 +239	 0.96 ŧ
	 					75+	 14333	 14173	 -160	 1.01
	
	 Race	 	 	 	
	 					White	 27174	 28161	 +987	 0.96 ŧ
	 					Black	 351	 285	 -66	 1.23 ŧ
	 					Other	 124	 166	 +42	 0.75 ŧ
	
	 Urban/Rural**	 	 	 	
	 					MSAγ	 13029	 13247	 +218	 0.98
	 					>20,000	 6623	 6852	 +229	 0.97ŧ
	 					10-20,000	 6079	 6491	 +412	 0.94 ŧ
	 					Rural	 1918	 2022	 +104	 0.95 ŧ
Male	 Age	 	 	 	
	 					0-19	 128	 97	 -31	 1.32ŧ
	 					20-44	 783	 923	 +140	 0.85 ŧ
	 					45-64	 6526	 7278	 +752	 0.90 ŧ
	 					65-74	 8329	 8635	 +306	 0.96 ŧ
	 					75+	 14115	 15051	 +936	 0.94 ŧ
	
	 Race	 	 	 	
	 					White	 29305	 31488	 +2183	 0.93 ŧ
	 					Black	 451	 320	 -131	 1.41ŧ
	 					Other	 125	 176	 +51	 0.71ŧ
	
	 Urban/Rural**	 	 	 	
	 					MSAγ	 13709	 14540	 +831	 0.94 ŧ
	 		   >20,000	 7532	 7712	 +180	 0.98 ŧ
	 					10-20,000	 6517	 7428	 +911	 0.88 ŧ
	 					Rural	 2123	 2304	 +181	 0.92ŧ
§	Computed	using	indirect	standardization	with	sex-	and	age-specific	rates	for	1994-1996	as	the	standard		
*	Standardized	mortality	ratio	(SMR)	equals	the	observed	number	of	deaths	divided	by	the	expected	number.	
**	Urban/rural	groupings	were	obtained	from	the	2005	Iowa	Health	Fact	Book	(see	http://www.public-health.
uiowa.edu/factbook/)
γ Metropolitan	statistical	area	(MSA)	consists	of	one	or	more	counties	that	contain	a	city	of	50,000		
or	more	inhabitants
ŧ SMR	is	statistically	significant	from	1.00	at	0.05	level	of	significance.
These data show that 
progress with saving lives 
from cancer has been
relatively widespread 
across Iowa. Furthermore, 
this progress has been
accomplished primarily 
with the major cancer 
sites of prostate, female
breast, colon & rectum, 
and lung.
0
The State Health Registry of Iowa is participating in 
around two dozen funded studies during 007. Brief 
descriptions of a few of these studies are provided.
The Agricultural Health Study
The Agricultural Health Study is a long-term study of  
agricultural exposures (including pesticides) and chronic  
disease (especially cancer) among commercial or private  
pesticide applicators (and their spouses, if married) in 
Iowa and North Carolina. The study is funded primarily  
by the National Cancer Institute. We are in the 5th year 
of the study, which received renewed funding at the end 
of 003 for continuation through 00. 
In the first five years, 9,65 subjects (5,564 in Iowa 
and 3,094 in North Carolina) were enrolled in the study. 
This total for Iowa included 3,77 private applicators, 
,77 spouses of private applicators, and 4,96 commercial 
applicators. Enrollment consisted of completing question-
naires about past exposures and health. The second phase 
of the study for private applicators and their spouses  
was completed at the end of 003. It involved a telephone 
interview, a mailed dietary questionnaire, and collection 
of a cheek cell sample from all consenting cohort  
members. The telephone interview asked about pesticide 
use since enrollment, current farming and work practices, 
and health changes. The dietary health questionnaire  
asked about cooking practices and types of foods eaten.  
Cooking practices and diet may play a role in cancer and 
other health conditions. The cheek cells will be used to 
understand possible links between genetics, exposures, 
and disease. For commercial applicators, the second 
phase of the study was completed at the end of 005.  
The study’s third phase began in 005, involves updating 
information about exposures and health, and is ongoing. 
Since 997, cohort members have been linked annually  
to mortality and cancer registry incidence databases  
in both states. In addition, mortality data on the cohort 
are being obtained from the National Death Index.  
More information about recent results from this study,  
the study background, frequently asked questions, other 
resources (internet & telephone) for agricultural health 
information, references for publications to date, and 
information for scientific collaborators can be found at 
the website, www.aghealth.org. The abstract and/or full 
Research Projects during 2007
text is available for study publications at the website.  
The cancer-related references for some of the recent  
publications are provided in the last section of this report. 
Lung Cancer Care Outcomes/Surveillance 
Consortium 
This study involves a statistical coordinating center, 
the State Health Registry of Iowa, and six other primary 
data collection and research sites across the United 
States. Across these sites, we are conducting population-
based research in the areas of access to care and patterns  
of care. We are evaluating the reasons for particular care 
decisions by patients and their physicians, as well as  
variation in dissemination of modern care protocols and 
practices in different geographic areas. We are investigat-
ing the effects of these decisions and practices on patient 
outcomes, including quality of life, for patients with lung 
or colorectal cancer. In Iowa, this study was limited to 
lung cancer patients. We enrolled over ,000 lung cancer 
patients newly diagnosed between June 003 and March 
005. We are currently working on the medical record 
abstraction component. 
Studies involving Non-Hodgkin Lymphoma (NHL)
The State Health Registry of Iowa (SHRI), along with  
researchers at the Mayo Clinic participated in a  
collaborative, population-based case-control study of  
NHL involving researchers at the National Cancer Institute 
and three other Surveillance, Epidemiology, and End 
Results (SEER) registries. The main objective of the study 
was to better characterize risk factors for NHL. In Iowa, 
364 live patients newly diagnosed with NHL between July 
, 99 and June 30, 000 were enrolled. A similar number 
of population controls participated. Blood samples were 
sought from study participants. The SHRI also coordinated 
the acquisition of pathology reports, slides and tissue 
blocks from all SEER centers. The slides were reviewed  
to determine the reliability of NHL pathologic classifica-
tion. More recently, we are collaborating with researchers 
at the Mayo Clinic to investigate whether genes with  
functional, common variant polymorphisms involved  
in immune function and regulation are associated with  
overall survival from NHL among these patients. To 
achieve this aim, medical record reviews were performed 
to obtain more detailed information on the treatment 
received for NHL. In addition, NHL patients not diagnosed 
and/or treated at the University of Iowa Hospitals and 

Clinics or at the Mayo Clinic are being contacted by 
Registry staff. If they have a family history of hematopoi-
etic cancer, they are being invited to participate by  
providing a family history and by providing blood samples 
from themselves and their relatives. These research  
activities resulted in several publications during 006. 
The references for some of these are provided in the last 
section of this report. 
Second Cancer Studies
Over the past two decades, the State Health Registry  
of Iowa has participated in several second cancer studies. 
These have consisted of cohorts with a first cancer of the 
cervix, ovary, testis, uterus, female breast, non-Hodgkin’s 
lymphoma, or Hodgkin’s disease. They have been  
conducted primarily in collaboration with the Radiation 
Epidemiology Branch at the National Cancer Institute and 
other registries in North America and Europe. Generally 
these studies evaluate the treatment received for the first 
cancer and the risk it places on the patient for develop-
ment of a second cancer. They typically involve medical 
record review and pathology material retrieval.  
The WECARE (Women’s Environmental Cancer and 
Radiation Epidemiology) Study is another example of a 
second cancer study. This study is designed to examine 
the interaction of gene carrier status and radiation  
exposure in the etiology of female breast cancer. Data 
collection has been recently completed and not only 
involved medical record review, but also participant 
interviews and blood samples. 
Results from the second cancer studies have provided 
important medical information and will continue to do so 
in the future.  
Geographical Information Systems
The State Health Registry of Iowa is involved with 
research utilizing a geographical information system to 
develop and test a methodology for identifying regions  
of excess cancer burden for breast and colorectal cancer 
in Iowa. It will refine measures of geographic access to 
cancer prevention, treatment and screening services in 
Iowa by computing values using fine-scaled geographic 
data on individuals, the spatial choices of individuals  
and the locations of service providers. A regional simula-
tion workbench will generate the expected range and  
variations in the cancer burden measures for small  
geographic areas of Iowa based on local demographic 
characteristics of the area and statewide cancer burden 
rates. Results can be used to plan more appropriate cancer 
prevention and control programs.
The Registry is also involved with a prostate cancer 
study that is producing an edited book of key geocoding 
issues and preparing “A Primer on Geocoding for Prostate 
Cancer Prevention and Control Activities”. This study is 
conducting research and field-testing to compare and 
evaluate different geocoding methods. Further develop-
ment will be done in the area of masking the locations  
of geocoded prostate cancer incidences sufficient to guar-
antee their confidentiality, yet leaving them fit for use in 
prostate cancer prevention and control.
The Registry has also provided data for maps created 
for use by the Iowa Consortium for Comprehensive Cancer 
Control. The maps were created by Dr. Gerard Rushton, 
Professor of Geography at the University of Iowa, and 
graduate students Kristen Beyer, Zunqiu Chen, and 
Veronica Escamilla. These maps can be used for planning 
purposes for cancer prevention and control activities. 
They can be viewed at http://www.uiowa.edu/~gishlth/
ICCCCMaps/index.htm.
Pooled Analyses
Today, researchers are increasingly looking to combine 
their study data with that of other studies evaluating simi-
lar outcomes. The State Health Registry of Iowa has been 
involved with such pooling activities for studies involving 
residential radon and lung cancer, diet and cancer,  
drinking water and bladder cancer, and non-Hodgkin’s 
lymphoma. During 006 these activities have resulted  
in several publications, which are listed in the last section 
of this report. 
  
SEER Patterns of Care Studies
This is a collaborative set of studies between the 
National Cancer Institute and its 4 SEER Registries.  
In 007, we will investigate state-of-the-art therapies for 
in situ and early stage female breast cancer, stage II/III 
colorectal cancer, and non-small cell lung cancer. Across 
these cancer sites, 35 patients will be eligible at the State 
Health Registry of Iowa and each will have been newly 
diagnosed during 005. The SHRI has been involved  
with these types of studies over the past 0 years.  
The collected data have resulted in several publications,  
a few of which were published in 006 and are listed in 
the references provided in the last section of this report. 

The Iowa Women’s Health Study
This is a population-based cohort of 4,37 Iowa 
women, aged 55-69 in 96, who were recruited to  
determine whether diet, body fat distribution and other 
risk factors were related to cancer incidence. Exposure 
and lifestyle information was collected in a baseline 
mailed survey and subsequently in several follow-up 
mailed surveys. Mortality and cancer incidence has 
been ascertained since 96 through linkage to the State 
Health Registry of Iowa databases and the National 
Death Index. The project has been extremely productive 
with over 00 publications, some of which occurred in 
006 and are listed in the references provided in the 
last section of this report. This year SHRI personnel are 
obtaining pathologic materials for several hundred 
women in this study who have been diagnosed with 
colorectal (CRC) cancer as part of a collaborative study 
with researchers at the Mayo Clinic. The primary aims 
of the study are to examine associations between envi-
ronmental factors and CRC subtypes exhibiting DNA pat-
terns defined by a microsatellite instability phenotype, 
Ki-ras mutation status, p53 mutation status, and gene-
specific methylation patterns. The study will be ongoing 
for the next several years. 
Cooperative Agreements and Other Registries
The SHRI maintains cooperative agreements with  
several hospital cancer registries and other agencies/
entities. Some of the latter include:
• Iowa Department of Public Health
*  Iowa Consortium for Comprehensive Cancer   
 Control
•  The University of Iowa
 - Center for Health Effects of Environmental   
   Contamination
 - Center for Public Health Statistics
 - Environmental Health Sciences Research Center
 - Health Effectiveness Research Center
 - Holden Comprehensive Cancer Center
 - Iowa Center for Agricultural Safety and Health
 - Injury Prevention Research Center
 - Preventive Intervention Center 
 - Reproductive Molecular Epidemiology Research  
   & Education Program
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